Pankaj Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2146334/publications.pdf

Version: 2024-02-01

567281 395702 36 1,865 15 33 citations h-index g-index papers 39 39 39 2806 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Anemia and Iron Deficiency in Heart Failure. Circulation, 2018, 138, 80-98.	1.6	352
2	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet, The, 2015, 386, 552-561.	13.7	350
3	High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart, 2014, 100, 855-861.	2.9	311
4	Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension, 2017, 69, 1113-1120.	2.7	150
5	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. Journal of the American Academy of Dermatology, 2016, 74, 841-850.	1.2	135
6	Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension, 2017, 70, 1042-1048.	2.7	132
7	How to Screen for Non-Adherence to Antihypertensive Therapy. Current Hypertension Reports, 2016, 18, 89.	3.5	62
8	Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. Journal of Public Health, 2022, 44, 234-245.	1.8	60
9	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension, 2022, 79, 12-23.	2.7	51
10	Cov-MS: A Community-Based Template Assay for Mass-Spectrometry-Based Protein Detection in SARS-CoV-2 Patients. Jacs Au, 2021, 1, 750-765.	7.9	29
11	Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment. Hypertension, 2018, 72, 1117-1124.	2.7	23
12	Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. Hypertension, 2020, 75, 510-515.	2.7	23
13	Pleiotropic effects of statins in hypercholesterolaemia: a prospective observational study using a lipoproteomic based approach. Lancet, The, 2015, 385, S21.	13.7	19
14	Biochemical Urine Testing of Adherence to Cardiovascular Medications Reveals High Rates of Nonadherence in People Attending Their Annual Review for Type 2 Diabetes. Diabetes Care, 2019, 42, 1132-1135.	8.6	16
15	Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence. Hypertension, 2019, 74, 652-659.	2.7	15
16	Nonâ€adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatographyâ€ŧandem mass spectrometry (results of a prospective) Tj ETQq0 0 0 rgB	T /Øxierloc	k 1 0 5Tf 50 137
17	How I treat anemia in heart failure. Blood, 2020, 136, 790-800.	1.4	14
18	How do specialist trainee doctors acquire skills to practice patient-centred care? A qualitative exploration. BMJ Open, 2018, 8, e022054.	1.9	13

#	Article	IF	Citations
19	Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis. Clinical Pharmacology in Drug Development, 2018, 7, 587-596.	1.6	13
20	Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Pressure, 2021, 30, 282-290.	1.5	13
21	<p>Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening</p> . Patient Preference and Adherence, 2019, Volume 13, 537-547.	1.8	12
22	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography–tandem mass spectrometry-based urine analysis. European Heart Journal -Cardiovascular Pharmacotherapy, 2021, 7, 296-301.	3.0	12
23	Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT). Diabetes Care, 2021, 44, 1419-1425.	8.6	11
24	Effectiveness of the Ready to Reduce Risk (3R) complex intervention for the primary prevention of cardiovascular disease: a pragmatic randomised controlled trial. BMC Medicine, 2020, 18, 198.	5.5	6
25	The Ready to Reduce Risk (3R) Study for a Group Educational Intervention With Telephone and Text Messaging Support to Improve Medication Adherence for the Primary Prevention of Cardiovascular Disease: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11289.	1.0	4
26	Measurements of Antihypertensive Medications in Blood and Urine. Updates in Hypertension and Cardiovascular Protection, 2018, , 29-41.	0.1	4
27	Reducing vitamin D requests in a primary care cohort: a quality improvement study. BJGP Open, 2020, 4, bjgpopen20X101090.	1.8	4
28	Review of the methods to measure non-adherence with a focus on chemical adherence testing. Translational Metabolic Syndrome Research, 2022, 5, 1-9.	0.8	4
29	Achieving optimal adherence to medical therapy by telehealth: Findings from the ORBITA medication adherence subâ€study. Pharmacology Research and Perspectives, 2021, 9, e00710.	2.4	3
30	No cases of asymptomatic SARS-CoV-2 infection among healthcare staff in a city under lockdown restrictions: lessons to inform †Operation Moonshotâ€. Journal of Public Health, 2020, , .	1.8	3
31	Measuring adherence to antihypertensive medication using an objective test in older adults attending primary care: cross-sectional study. Journal of Human Hypertension, 2022, 36, 1106-1112.	2.2	3
32	Response by Anand and Gupta to Letter Regarding Article, "Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies― Circulation, 2018, 138, 2976-2977.	1.6	2
33	The feasibility of theÂPAM intervention to support treatment-adherence in people with hypertension in primary care: a randomised clinical controlled trial. Scientific Reports, 2021, 11, 8897.	3.3	1
34	Serum lipoprotein(a) concentrations do not change significantly in the immediate seven-day period post myocardial infarction. Annals of Clinical Biochemistry, 2015, 52, 502-505.	1.6	0
35	Lessons from treatment resistant hyperlipidaemia. Oxford Medical Case Reports, 2016, 2016, omw076.	0.4	0
36	The curious case of an invisible dog: a patient with non-psychiatric visual hallucinations. Oxford Medical Case Reports, 2016, 2016, 9-11.	0.4	0